Vai al contenuto principale della pagina

AMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance / / Sang Geon Kim, Il Je Cho and Hee Yeon Kay



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Autore: Kim Sang Geon Visualizza persona
Titolo: AMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance / / Sang Geon Kim, Il Je Cho and Hee Yeon Kay Visualizza cluster
Pubblicazione: New York, : Nova Science Publishers, c2010
Edizione: 1st ed.
Descrizione fisica: 1 online resource (69 p.)
Disciplina: 616.3/6207
Soggetto topico: Insulin resistance - Molecular aspecsts
Liver - Diseases - Molecular aspecsts
Protein kinases
Altri autori: ChoIl Je  
KayHee Yeon  
Note generali: Description based upon print version of record.
Nota di bibliografia: Includes bibliographical references (p. [33]-49) and index.
Nota di contenuto: Introduction: Insulin signaling in hepatocytes -- Clinical and preclinical drugs for the treatment of hepatic insulin resistance.
Sommario/riassunto: Hepatic insulin resistance and altered insulin metabolism, as characterized by the desensitization of hepatic parenchymal cells to insulin, play a role in the pathogenesis of liver disease, particularly resulting in steatosis and steatohepatitis. By the same token, type II diabetic patients are at higher risk for developing liver diseases, including steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma. On the other hand, established liver disease from any cause leads to glucose intolerance and peripheral insulin resistance systemically. The link between insulin resistance and liver pathology reviewed in this book suggests that insulin resistance is closely related with a variety of liver diseases. Recent evidence indicates that the AMP activating protein kinase (AMPK) in conjunction with p70 ribosomal S6 kinase 1 (S6K1) serves as a key signaling pathway regulating insulin-dependent physiological functions; thus, this pathway serves as a target for the therapy of diseases associated with insulin resistance. In this chapter, the regulatory role of the AMPK-S6K1 pathway is discussed in terms of enhancing insulin receptor signaling with insulin receptor substrate-1/2 and phosphatidylinositol phosphate kinase activity, which may contribute to preventing and/or treating insulin resistance in the liver.
Titolo autorizzato: AMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance  Visualizza cluster
ISBN: 1-61761-457-2
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910967542303321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Serie: Hepatology research and clinical developments series.